Theravance Biopharma, Inc. - 8-K Filing
Theravance Biopharma completed a merger with Zymeworks Inc., converting shares into $17.00 cash and contingent value rights (CVRs) on September 23, 2026. (Items: 2.01 of this Current Report on Form 8-K is incorporated herein by reference, 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, 9.01 Financial Statements and Exhibits)
Tickers: $TBPH